Evidence map›Paper›PMID 40652066›Full record

ArticleScientific reports2025

Reduced rates of diabetic retinopathy complications with use of continuous glucose monitoring.

Amer F Alsoudi, Karen M Wai, Euna Koo, Eubee Koo, Prithvi Mruthyunjaya, Ehsan Rahimy

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amer F AlsoudiDepartment of Ophthalmology, Baylor College of Medicine, Houston, TX, USA.
Karen M WaiHorngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Euna KooHorngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Eubee KooHorngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Prithvi MruthyunjayaHorngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Ehsan RahimyHorngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA. rahimye@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elucidating the outcomes of patients using continuous glucose monitoring (continuous glucose monitoring) in day-to-day clinical practice could help expand optimal practice guidelines in prevention and mitigation of diabetic retinopathy (DR). Retrospective cohort study. Subjects, Participants, and/or Controls: 13,302 patients with NPDR initiated on continuous glucose monitoring, compared with 179,079 patients with NPDR not initiated on continuous glucose monitoring before propensity score matching (propensity score matching) at one year. TriNetX (Cambridge, MA, USA), was used to identify patients diagnosed with NPDR stratified by initiation of continuous glucose monitoring or not with at least six months of follow-up. propensity score matching controlled for baseline demographics and medical comorbidities. After propensity score matching, 12,730 patients were subsequently analyzed in each cohort. Use of continuous glucose monitoring was associated with lower risk of vision threatening complications (DME: hazards ratio [HR], 0.87, 95% CI, 0.82-0.93; P < .001; PDR: HR, 0.74, 95% CI, 0.66-0.82; P < .001; VH: HR, 0.55, 95% CI, 0.47-0.66; P < .001; TRD: HR, 0.42, 95% CI, 0.27-0.68; P = .027), and need for ocular intervention (anti-VEGF injection: HR, 0.72, 95% CI, 0.65-0.80; P < .001; PRP: HR, 0.53, 95% CI, 0.44-0.64; P < .001; PPV: HR, 0.37, 95% CI, 0.26-0.51; P < .001) among patients with NPDR when compared with matched patients not using continuous glucose monitoring at 1 year. Similar associations at two years were found. continuous glucose monitoring use in patients with NPDR without prior ocular therapy was associated with lower risk of progression to vision threatening complications as well as need for ocular intervention at one year and two years, highlighting that glycemic variability and time in range are important factors influencing the risk of complications from diabetic eye disease.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringDiabetic RetinopathyAgedContinuous Glucose MonitoringFemaleHumansMaleMiddle AgedPropensity ScoreRetrospective StudiesBlood GlucoseContinuous glucose monitoringDiabetic macular edemaPanretinal photocoagulationPars plan vitrectomyProliferative diabetic retinopathyVascular endothelial growth factor

Identifiers

PMID40652066
PMCPMC12255799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.